Board Members & Investor

Board of Directors

Craig Belcher

Giovanni Mariggi

Giovanni is a Partner at medicxi and a member of the co-founding team. He is also the chairman of Vicebio’s board of directors.

Prior to medicxi, Giovanni was a Principal at Index Ventures for four years, having joined in 2012. Giovanni currently serves on the boards of a number of portfolio companies, including Vaderis, Vicebio, Gadeta and Aura Biosciences (AURA).

Craig Belcher

Craig Belcher

Craig has been with UniQuest, the commercialisation company of The University of Queensland, since 2004 and is currently the Senior Director and Head of Life Sciences. Prior roles at UniQuest included Senior Director Industry Engagement and Manager of Innovation and Commercial Development. Before joining UniQuest, Craig was a Business Development Manager at Cambridge Antibody Technology in the UK before the company was listed on the NASDAQ and acquired by AstraZeneca. He has more than 20 years of deal-making and IP commercialisation experience – negotiating agreements totalling more than $100 million – including securing venture capital to establish start-up companies and licensing with major pharma and biotechnology companies based in the US, UK, Europe and Australia. As well as Vicebio Ltd, Craig serves on the board of a number of UniQuest portfolio companies, including Liperate Pty Ltd and a start-up company in stealth mode, and is a past director of Dendright Pty Ltd, Nexgen Plants Pty Ltd, TenasiTech Pty Ltd and Aquahydrex Pty Ltd.

Giovanni Della Cioppa

Emmanuel Hanon

Emmanuel Hanon (Manu) is the Chief Executive Officer of Vicebio and has more than 20 years experience in vaccine research & development. He led the merger between Novartis and GSK R&D organisations and ran global vaccines R&D at GSK for 7 years. Manu has broad functional knowledge including R&D, medical, clinical, regulatory, technical CMC, manufacturing and quality operations. At GSK, he oversaw the discovery and development of four major vaccines : quadrivalent influenza (Fluarix and Flulaval Quadrivalent), shingles (Shingrix), malaria (Mosquirix), and RSV older adult vaccines.

Manu received his Doctorate in Veterinary Medicine and completed his PhD in Veterinary Sciences at the University of Liège, Belgium. Additionally,  he spent 2 years at Imperial College (St Mary’s), London UK, as a post-doctoral researcher. 

Vicebio investor

Clamped Vaccine

Medicxi is a healthcare-focused investment firm with the mission to create and invest in companies across the full drug development continuum. Leveraging deep expertise in drug development and company creation spanning over two decades, medicxi invests in early and late-stage therapeutics with a product vision that can fulfill a clear unmet medical need.